On May 1, 2025, Halozyme Therapeutics, Inc. held its Annual Meeting where stockholders voted on three key proposals: two directors were elected, the executive compensation was approved, and Ernst & Young was ratified as the accounting firm for 2025. Out of 123,533,310 shares, 112,767,003 were represented, demonstrating strong participation.